|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,574.00 JPY | -0.31% |
|
-0.85% | -23.12% |
| 11:20pm | FDA approves Daiichi Sankyo's fam-trastuzumab deruxtecan-nxki for two breast cancer indications | RE |
| 05-15 | Breast Cancer Treatment from Daiichi Sankyo, AstraZeneca Approved in U.S. | DJ |
| Capitalization | 4,684B 29.52B 25.4B 23.22B 22.16B 40.62B 2,832B 41.29B 279B 108B 1,344B 111B 108B | P/E ratio 2026 |
19.7x | P/E ratio 2027 * | 14.1x |
|---|---|---|---|---|---|
| Enterprise value | 4,161B 26.22B 22.56B 20.63B 19.68B 36.09B 2,516B 36.68B 248B 95.78B 1,194B 98.41B 96.3B | EV / Sales 2026 |
2.39x | EV / Sales 2027 * | 1.78x |
| Free-Float |
95.99% | Yield 2026 |
2.82% | Yield 2027 * | 3.53% |
Last Transcript: Daiichi Sankyo Company, Limited
| 1 day | -0.31% | ||
| 1 week | -0.85% | ||
| Current month | -0.56% | ||
| 1 month | -9.11% | ||
| 3 months | -12.37% | ||
| 6 months | -26.56% | ||
| Current year | -23.12% |
| 1 week | 2,531.5 |  | 2,758.5 |
| 1 month | 2,443 | | 3,016 |
| Current year | 2,443 | | 3,625 |
| 1 year | 2,443 | | 4,178 |
| 3 years | 2,443 | | 6,257 |
| 5 years | 1,981 | | 6,257 |
| 10 years | 730.5 | | 6,257 |
| Manager | Title | Age | Since |
|---|---|---|---|
Hiroyuki Okuzawa
CEO | Chief Executive Officer | 62 | 31/03/2025 |
Tomohiro Kodama
DFI | Director of Finance/CFO | - | 31/03/2026 |
John Tsai
CTO | Chief Tech/Sci/R&D Officer | 59 | 31/03/2026 |
| Director | Title | Age | Since |
|---|---|---|---|
Hiroyuki Okuzawa
BRD | Director/Board Member | 62 | 20/06/2021 |
Yasuhiro Komatsu
BRD | Director/Board Member | 68 | 31/05/2022 |
| Director/Board Member | 62 | 16/06/2024 |
| Name | Varia. Jan 1. | Weight | AuM | |
|---|---|---|---|---|
 | +12.67% | 2.69% | 118 M€ |
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
| -0.31% | -0.85% | -23.42% | -44.95% | 29.52B | |
| -0.00% | +5.95% | +37.04% | +131.28% | 896B | |
| -1.77% | +2.44% | +51.53% | +42.09% | 546B | |
| -0.18% | +4.39% | +15.80% | +43.52% | 372B | |
| +0.88% | +2.38% | +25.60% | +13.56% | 328B | |
| -0.79% | +2.16% | +34.41% | +13.60% | 282B | |
| -0.10% | +2.93% | +29.16% | +26.15% | 283B | |
| -1.79% | 0.00% | +48.90% | -4.29% | 275B | |
| +0.91% | +3.07% | -31.12% | -48.50% | 206B | |
| -2.22% | -1.62% | +20.10% | +39.73% | 176B | |
| Average | -0.54% | +2.12% | +20.80% | +21.22% | 339.29B | |
| Weighted average by Cap. | -0.50% | +3.34% | +30.48% | +49.21% |
| 2026 | 2027 * | |
|---|---|---|
| Net sales | 2,133B 13.44B 11.57B 10.58B 10.09B 18.5B 1,290B 18.8B 127B 49.1B 612B 50.45B 49.37B | 2,350B 14.81B 12.74B 11.65B 11.12B 20.38B 1,421B 20.72B 140B 54.09B 674B 55.57B 54.38B |
| Net income | 304B 1.91B 1.65B 1.51B 1.44B 2.63B 184B 2.68B 18.06B 6.99B 87.16B 7.18B 7.03B | 335B 2.11B 1.82B 1.66B 1.59B 2.91B 203B 2.95B 19.93B 7.71B 96.18B 7.93B 7.76B |
| Net Debt | -523B -3.3B -2.84B -2.59B -2.47B -4.54B -316B -4.61B -31.11B -12.04B -150B -12.37B -12.1B | -500B -3.15B -2.71B -2.48B -2.37B -4.34B -302B -4.41B -29.74B -11.51B -143B -11.82B -11.57B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 15/05/26 | 2,574.00 ¥ | -0.31% | 8,793,800 |
| 14/05/26 | 2,582.00 ¥ | -5.27% | 10,516,700 |
| 13/05/26 | 2,725.50 ¥ | -0.46% | 7,061,800 |
| 12/05/26 | 2,738.00 ¥ | +3.36% | 13,241,500 |
| 11/05/26 | 2,649.00 ¥ | +2.04% | 11,532,500 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- 4568 Stock
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition